QS Research · Michael Burry's Scion Capital analyst template · 2006
Viatris Inc (VTRS)
As of 2026-11-18 · 11/15 boxes filled from SEC filings and market data
Report price $20.28 (close 2026-11-18); latest close $19.63 (2026-11-20), -3.2% since the report; figures re-marked at the latest close
Conclusion: WATCH
Conviction low · base case +65% · downside -46% · upside +82%
The market is pricing $34.78B of enterprise value at 12.4x GAAP EBITDA and 16.5x free cash flow, a 9.1% FCF yield on $2.11B, even though EBITDA is almost entirely the $2.81B of D&A and EBIT is -$4.6M; cash flow, not earnings, is what the price buys. That cash flow and the peer discount are real, but with revenue growth of -3.0%, net debt/EBITDA of 4.1x and a reverse DCF needing +2.5% growth a year for 10 years, the setup does not clear the bar at $20.28, so the call is WATCH. Downside at $10.57 (-47.9%): -20.0% earnings at a compressed EV/EBITDA of 10.54x (today 12.4x). Base at $32.39 (+59.7%): EV/EBITDA at 17.35x, the peer median EV/EBITDA (4 peers in the comps table: TEVA 20.5x, AMRX 15.1x, OGN 12.8x, PFE 19.6x). Upside at $35.63 (+75.7%): the base case's multiple on +10% earnings. The reward/risk is 1.58.
Key numbers
- Share price: $19.63
- Market cap: $22.50B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $14.73B
- EV / EBITDA (TTM): 12.1x
- FCF yield: 9.4%
- Earnings-quality flags (FY Dec 2025): Impairments -$2.94B (84% of net income)
- EV / FCF (TTM): 16.1x
- Revenue growth (latest fiscal year): -3.0%
The 15 boxes
- ✓ 1. Long-form business notes
Viatris Inc. is the Nov 2020 combination of Mylan and Pfizer's Upjohn business; the entity was Upjohn before changing its name to Viatris Inc. and it sells generics, iconic brands and an expanding innovative portfolio through four segments in more than 165 countries. The latest 10-K shows a smaller footprint than the FY2020 filing (27 sites and more than 30,000 employees versus about 50 sites and about 45,000) after divesting biosimilars, women's health, API and OTC, and it is cutting up to about 10% of staff under a Feb 2026 restructuring. FY2025 revenue was $14.30B and operating cash flow $2.32B, while GAAP operating income was -$2.66B; TTM revenue is $14.73B with operating cash flow $2.49B. I value on current TTM/FY2025 GAAP operating cash flow and GAAP operating income, using a GAAP (not adjusted) EBITDA basis if an EBITDA measure is needed.
- ○ 2. Competitive advantage
Viatris has company-claimed scale — 27 manufacturing, packaging and distribution sites and a portfolio spanning branded, generic and complex drugs — but the post-2020 financial record does not show a durable advantage: revenue fell from $17.89B in FY2021 to $14.30B in FY2025, gross profit fell from $5.58B to $5.01B, and operating income was -$2.66B in FY2025 and -$4.6M TTM. Operating returns are volatile and net income is negative in FY2021, FY2024 and FY2025, while operating cash flow remains positive ($2.32B FY2025; $2.49B TTM). The sources do not name specific competitors; they list competition factors and show customer concentration in distributors. This looks like a scale/access business without demonstrated pricing power or stable returns.
- ✓ 3. 10-Q takeaways
The Q3 2026 10-Q shows a flat top line with better margins: total revenues of $3,749.5 million versus $3,759.9 million, GAAP gross margin 38.4% versus 36.5% and adjusted gross margin 58.0% versus 56.0%, with ~$115.2 million of new product sales offsetting ~$126.1 million of base-business erosion. The reported net loss of $325.3 million (diluted $(0.28)) is a tax-driven GAAP figure, not an operating one: the quarter's income tax provision was $453.2 million versus $120.3 million, while company-defined adjusted EBITDA was $1,195.7 million and adjusted EPS $0.71. Cash was strong — $899.4 million of operating cash flow and $813.7 million of free cash flow in the quarter — and the company raised the midpoints of all 2026 guidance ranges. Two disclosed drags carry into Q4 2026: the Nashik, India supply suspension (~$100 million of Q3 revenue impact and ~$100 million expected in Q4) and the EWSR restructuring program (up to ~10% workforce reduction, $700–$850 million of expected pre-tax charges).
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.